View Future GrowthSELLAS Life Sciences Group 過去の業績過去 基準チェック /06SELLAS Life Sciences Groupの収益は年間平均-6.4%の割合で減少していますが、 Biotechs業界の収益は年間 増加しています。収益は年間30% 77.6%割合で 減少しています。主要情報-6.40%収益成長率27.32%EPS成長率Biotechs 業界の成長17.04%収益成長率-77.64%株主資本利益率-37.90%ネット・マージンn/a前回の決算情報31 Dec 2025最近の業績更新Third quarter 2022 earnings released: US$0.34 loss per share (vs US$0.45 loss in 3Q 2021) Mar 18Second quarter 2022 earnings released: US$0.41 loss per share (vs US$0.30 loss in 2Q 2021) Aug 12すべての更新を表示Recent updatesSELLAS Life Sciences Group, Inc., Annual General Meeting, Jun 16, 2026Apr 25SELLAS Life Sciences Group, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.Mar 21New minor risk - Profitability Mar 20Sellas Life Sciences Group Announces Preclinical Data On SLS009 In AMLMar 18Sellas Life Sciences Group Announces Enrollment of First Patient in Newly Diagnosed First-Line AML Trial of SLS009Mar 13New major risk - Share price stability Jan 18SELLAS Life Sciences Group, Inc. Provides Update on Pivotal Phase 3 Regal Trial of Galinpepimut-S (GPS) in Acute Myeloid LeukemiaJan 01Forecast to breakeven in 2028 Dec 31New minor risk - Share price stability Dec 05Independent Director recently bought US$101k worth of stock Nov 23Sellas Life Sciences Announces Presentation of Phase 2 Data of Sls009 in Combination with Azacitidine and Venetoclax in Relapsed/Refractory Aml with Mds-Related Changes (Aml-Mr) At the 2025 American Society of Hematology (Ash) Annual MeetingNov 04New major risk - Financial position Oct 29SELLAS Life Sciences Group, Inc. to Present in Vivo Preclinical Data Demonstrating Statistically Significant Survival Benefit of SLS009 in T-Cell Prolymphocytic Leukemia AAt the European Society for Medical Oncology (ESMO) Congress 2025Oct 14Is SELLAS Life Sciences Group (NASDAQ:SLS) In A Good Position To Invest In Growth?Oct 08SELLAS Life Sciences Group Announces Virtual R&D Day on October 29, 2025, Featuring Updates on GPS and SLS009 ProgramsOct 02SELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 Regal Trial of GPS in AML Without ModificationAug 08Sellas Life Sciences Group, Inc. Meets All Primary Endpoints in Phase 2 Trial of Sls009 in R/R Aml and Receives Fda Guidance to Advance into First-Line Therapy StudyJul 16SELLAS Life Sciences Group, Inc. Appoints Linghua Wang to Scientific Advisory BoardJul 07New minor risk - Share price stability Jul 01Is SELLAS Life Sciences Group (NASDAQ:SLS) In A Good Position To Invest In Growth?Jun 25New minor risk - Profitability Jun 17Sellas Life Sciences Group, Inc. Appoints Philip C. Amrein and Alex Kentsis to the Scientific Advisory BoardJun 06Sellas Life Sciences Group, Inc. Presents Preclinical Efficacy of Sls009 in Asxl1 Mutated Colorectal Cancer At 2025 Asco Annual MeetingJun 02New major risk - Financial position May 15SELLAS Life Sciences Group, Inc. Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of Sls009 R/R AMLMay 15SELLAS Life Sciences Group, Inc. Unveils Breakthrough Preclinical Data Highlighting Efficacy of Sls009 in Tp53 Mutated AML At the 2025 AACR ConferenceApr 28SELLAS Life Sciences Group, Inc., Annual General Meeting, Jun 17, 2025Apr 25SELLAS Life Sciences Group, Inc. to Present At the 2025 American Society of Clinical Oncology Annual MeetingApr 23SELLAS Life Sciences Group, Inc. Announces Cohort 3 Data from the Ongoing Phase 2 Trial of SLS009Apr 08No longer forecast to breakeven Mar 21SELLAS Life Sciences Group, Inc. Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCLFeb 21SELLAS Life Sciences Group, Inc. has filed a Follow-on Equity Offering in the amount of $24.998852 million.Jan 30New minor risk - Share price stability Jan 27Sellas Life Sciences Group, Inc. Announces Positive Outcome of Interim Analysis for Its Pivotal Phase 3 Regal Trial of GPS in Acute Myeloid LeukemiaJan 23SELLAS Life Sciences Group, Inc. Triggers Interim Analysis in Phase 3 Regal Trial of GPS in Acute Myeloid LeukemiaDec 11SELLAS Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of SLS009 inr/r AMLDec 10SELLAS Life Sciences Group, Inc. Announces Positive Data from Preclinical Studies Indicating ASXL1 Mutations as Predictor of Response to SLS009 in Solid CancersNov 28Here's Why SELLAS Life Sciences Group (NASDAQ:SLS) Must Use Its Cash WiselyNov 23New major risk - Financial position Nov 15SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to Galinpepimut-S (GPS) for the Treatment of Pediatric Acute Myeloid LeukemiaOct 15SELLAS Life Sciences Group, Inc. has completed a Follow-on Equity Offering in the amount of $20.999999 million.Aug 02SELLAS Life Sciences Group, Inc. has filed a Follow-on Equity Offering in the amount of $20.999999 million.Aug 01SELLAS Life Sciences Group, Inc. Receives European Medicines Agency Orphan Drug Designation for SLS009 for the Treatment of Acute Myeloid LeukemiaJul 08SELLAS Life Sciences Group, Inc. Announces U.S. FDA Rare Pediatric Disease Designation Granted to Sls009 for the Treatment of Pediatric Acute Lymphoblastic LeukemiaJun 25SELLAS Life Sciences Group, Inc. Announces Positive Recommendation from the Independent Data Monitoring Committee of the Phase 3 REGAL Trial in Acute Myeloid LeukemiaJun 18SELLAS Life Sciences Group (NASDAQ:SLS) Will Have To Spend Its Cash WiselyJun 18Price target decreased by 17% to US$5.83 May 16SELLAS Life Sciences Group, Inc. Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose LevelMay 03SELLAS Life Sciences Group, Inc., Annual General Meeting, Jun 20, 2024May 01SELLAS Life Sciences Group, Inc. Announces Positive Recommendation of Independent Data Monitoring Committee Following Completion of Enrollment in REGAL Phase 3 StudyApr 30SELLAS Life Sciences Group, Inc. Announces Positive Topline Data from the Phase 2a Study of Sls009 in r/r AMLMar 26New major risk - Shareholder dilution Mar 20SELLAS Life Sciences Group, Inc. has completed a Follow-on Equity Offering in the amount of $19.999797 million.Mar 20SELLAS Life Sciences Group, Inc. has filed a Follow-on Equity Offering.Mar 16New major risk - Share price stability Mar 12SELLAS Life Sciences Group, Inc. Announces Executive ChangesMar 08SELLAS Life Sciences Receives Compliance Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price RequirementFeb 17SELLAS Life Sciences Group, Inc. Receives FDA Fast Track Designation for SLS009 for Treatment of Relapsed/Refractory Acute Myeloid Leukemia and Provides Updated Data for Phase 2a Study of SLS009 in Relapsed/Refractory Acute Myeloid Leukemia PatientsJan 10SELLAS Life Sciences Group, Inc. has completed a Follow-on Equity Offering in the amount of $9 million.Jan 05SELLAS Life Sciences Group, Inc. Reports Positive Follow-Up Immune Response and Survival Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo® in Advanced Malignant Pleural MesotheliomaDec 28Sellas Life Sciences Announces First Patients Enrolled in 60 Mg Dose Cohort in Phase 2A Clinical Trial of Sls009 in Acute Myeloid LeukemiaDec 15SELLAS Life Sciences Group Receives a Letter from the Nasdaq Stock MarketDec 09Sellas Life Sciences Announces Positive Recommendation from Regal Independent Data Monitoring Committee of Galinpepimut-S in Acute Myeloid LeukemiaDec 05SELLAS Life Sciences Group, Inc. Reaches Target Enrollment Ex-China in Phase 3 Regal Trial of Galinpepimut-S in Acute Myeloid LeukemiaNov 29Consensus EPS estimates fall by 19% Nov 16SELLAS Life Sciences Group, Inc. Receives Favorable FDA Type C Meeting Feedback on Chemistry, Manufacturing, and Controls Biologics License Application Filing Strategy for Galinpepimut-SNov 14New major risk - Negative shareholders equity Nov 11SELLAS Life Sciences Group, Inc. Presents Positive Key Immunobiological and Clinical Data from Phase 1/2 Trial of galinpepimut-S in Combination with Keytruda in WT1+ Platinum-Resistant Advanced Ovarian Cancer at International Gynecologic Cancer Society 2023 Annual Global MeetingNov 07New major risk - Shareholder dilution Nov 03SELLAS Life Sciences Group, Inc. Announces Positive Initial Topline Phase 2a Data of SLS009 in Acute Myeloid LeukemiaOct 17SELLAS Life Sciences Group, Inc. Provides Update on Phase 3 Regal Clinical Trial for Galinpepimut-S in Acute Myeloid LeukemiaOct 15SELLAS Announces First Patient Dosed in Phase Ib/II Trial of SLS009 (GFH009) in Relapsed/Refractory Peripheral T-cell LymphomasOct 12New minor risk - Share price stability Oct 12SELLAS Life Sciences Group, Inc. Announces Positive Topline Data in Lymphoma Cohort from Sls009 Phase 1 Dose-Escalation Trial, Supporting Advancement to Phase 2 Clinical Study; Primary and Secondary Endpoints MetSep 22Consensus EPS estimates upgraded to US$0.87 loss Aug 17SELLAS Life Sciences Group (NASDAQ:SLS) Will Have To Spend Its Cash WiselyJul 13New major risk - Financial position Jul 02SELLAS Life Sciences Reports Positive Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo in Advanced Malignant Pleural MesotheliomaJun 29Sellas Life Sciences Group, Inc. Announces First Patient Dosed in Phase 2A Clinical Trial of GFH009 in Acute Myeloid LeukemiaJun 23Consensus EPS estimates fall by 12% Jun 01Consensus EPS estimates fall by 18% May 18Sellas Life Sciences Group, Inc. Announces Positive Topline Data from Gfh009 Phase 1 Dose-Escalation Trial in Acute Myeloid Leukemia Cohort Supporting Advancement to Phase 2 Clinical StudyMay 05Consensus revenue estimates increase by 200% Mar 23Third quarter 2022 earnings released: US$0.34 loss per share (vs US$0.45 loss in 3Q 2021) Mar 18Price target decreased by 25% to US$6.00 Mar 17SELLAS Life Sciences Group, Inc. Appoints John T. Burns as Chief Financial OfficerFeb 07SELLAS Life Sciences Group, Inc. Appoints Andrew Elnatan as Head of Regulatory Affairs, Chemistry, Manufacturing, and Controls and QualityJan 06Insufficient new directors Nov 16SELLAS Life Sciences Group (NASDAQ:SLS) Will Have To Spend Its Cash WiselySep 20Insufficient new directors Sep 09Second quarter 2022 earnings released: US$0.41 loss per share (vs US$0.30 loss in 2Q 2021) Aug 12SELLAS Life Sciences rises 9% after cancer drug shows promising result in animal study Aug 09Price target decreased to US$13.75 Apr 27Insufficient new directors Apr 27収支内訳SELLAS Life Sciences Group の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史NasdaqCM:SLS 収益、費用、利益 ( )USD Millions日付収益収益G+A経費研究開発費31 Dec 250-27111630 Sep 250-26121630 Jun 250-26101631 Mar 250-27111731 Dec 240-31121930 Sep 240-32122030 Jun 240-34142131 Mar 240-36142231 Dec 230-37142430 Sep 230-38142530 Jun 230-36142331 Mar 230-36142331 Dec 221-41132030 Sep 221-39121830 Jun 221-39111831 Mar 223-35111631 Dec 218-21111630 Sep 2110-18121530 Jun 2110-15121331 Mar 218-15111231 Dec 202-1710930 Sep 200-219930 Jun 200-289831 Mar 200-2710731 Dec 190-2810730 Sep 190-3411930 Jun 190-3210931 Mar 190-3612931 Dec 180-4113930 Sep 180-3710630 Jun 180-3212531 Mar 180-3011631 Dec 170-249630 Sep 170-2111930 Jun 170-23101231 Mar 170-2061231 Dec 160-18511質の高い収益: SLSは現在利益が出ていません。利益率の向上: SLSは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: SLSは利益が出ておらず、過去 5 年間で損失は年間6.4%の割合で増加しています。成長の加速: SLSの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: SLSは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 40.2% ) と比較することは困難です。株主資本利益率高いROE: SLSは現在利益が出ていないため、自己資本利益率 ( -37.9% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/03 23:16終値2026/05/01 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋SELLAS Life Sciences Group, Inc. 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。4 アナリスト機関James MolloyAlliance Global PartnersAydin HuseynovLadenburg Thalmann & CompanyJason McCarthyMaxim Group1 その他のアナリストを表示
SELLAS Life Sciences Group, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.Mar 21
Sellas Life Sciences Group Announces Enrollment of First Patient in Newly Diagnosed First-Line AML Trial of SLS009Mar 13
SELLAS Life Sciences Group, Inc. Provides Update on Pivotal Phase 3 Regal Trial of Galinpepimut-S (GPS) in Acute Myeloid LeukemiaJan 01
Sellas Life Sciences Announces Presentation of Phase 2 Data of Sls009 in Combination with Azacitidine and Venetoclax in Relapsed/Refractory Aml with Mds-Related Changes (Aml-Mr) At the 2025 American Society of Hematology (Ash) Annual MeetingNov 04
SELLAS Life Sciences Group, Inc. to Present in Vivo Preclinical Data Demonstrating Statistically Significant Survival Benefit of SLS009 in T-Cell Prolymphocytic Leukemia AAt the European Society for Medical Oncology (ESMO) Congress 2025Oct 14
SELLAS Life Sciences Group Announces Virtual R&D Day on October 29, 2025, Featuring Updates on GPS and SLS009 ProgramsOct 02
SELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 Regal Trial of GPS in AML Without ModificationAug 08
Sellas Life Sciences Group, Inc. Meets All Primary Endpoints in Phase 2 Trial of Sls009 in R/R Aml and Receives Fda Guidance to Advance into First-Line Therapy StudyJul 16
Sellas Life Sciences Group, Inc. Appoints Philip C. Amrein and Alex Kentsis to the Scientific Advisory BoardJun 06
Sellas Life Sciences Group, Inc. Presents Preclinical Efficacy of Sls009 in Asxl1 Mutated Colorectal Cancer At 2025 Asco Annual MeetingJun 02
SELLAS Life Sciences Group, Inc. Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of Sls009 R/R AMLMay 15
SELLAS Life Sciences Group, Inc. Unveils Breakthrough Preclinical Data Highlighting Efficacy of Sls009 in Tp53 Mutated AML At the 2025 AACR ConferenceApr 28
SELLAS Life Sciences Group, Inc. to Present At the 2025 American Society of Clinical Oncology Annual MeetingApr 23
SELLAS Life Sciences Group, Inc. Announces Cohort 3 Data from the Ongoing Phase 2 Trial of SLS009Apr 08
SELLAS Life Sciences Group, Inc. Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCLFeb 21
SELLAS Life Sciences Group, Inc. has filed a Follow-on Equity Offering in the amount of $24.998852 million.Jan 30
Sellas Life Sciences Group, Inc. Announces Positive Outcome of Interim Analysis for Its Pivotal Phase 3 Regal Trial of GPS in Acute Myeloid LeukemiaJan 23
SELLAS Life Sciences Group, Inc. Triggers Interim Analysis in Phase 3 Regal Trial of GPS in Acute Myeloid LeukemiaDec 11
SELLAS Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of SLS009 inr/r AMLDec 10
SELLAS Life Sciences Group, Inc. Announces Positive Data from Preclinical Studies Indicating ASXL1 Mutations as Predictor of Response to SLS009 in Solid CancersNov 28
SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to Galinpepimut-S (GPS) for the Treatment of Pediatric Acute Myeloid LeukemiaOct 15
SELLAS Life Sciences Group, Inc. has completed a Follow-on Equity Offering in the amount of $20.999999 million.Aug 02
SELLAS Life Sciences Group, Inc. has filed a Follow-on Equity Offering in the amount of $20.999999 million.Aug 01
SELLAS Life Sciences Group, Inc. Receives European Medicines Agency Orphan Drug Designation for SLS009 for the Treatment of Acute Myeloid LeukemiaJul 08
SELLAS Life Sciences Group, Inc. Announces U.S. FDA Rare Pediatric Disease Designation Granted to Sls009 for the Treatment of Pediatric Acute Lymphoblastic LeukemiaJun 25
SELLAS Life Sciences Group, Inc. Announces Positive Recommendation from the Independent Data Monitoring Committee of the Phase 3 REGAL Trial in Acute Myeloid LeukemiaJun 18
SELLAS Life Sciences Group, Inc. Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose LevelMay 03
SELLAS Life Sciences Group, Inc. Announces Positive Recommendation of Independent Data Monitoring Committee Following Completion of Enrollment in REGAL Phase 3 StudyApr 30
SELLAS Life Sciences Group, Inc. Announces Positive Topline Data from the Phase 2a Study of Sls009 in r/r AMLMar 26
SELLAS Life Sciences Group, Inc. has completed a Follow-on Equity Offering in the amount of $19.999797 million.Mar 20
SELLAS Life Sciences Receives Compliance Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price RequirementFeb 17
SELLAS Life Sciences Group, Inc. Receives FDA Fast Track Designation for SLS009 for Treatment of Relapsed/Refractory Acute Myeloid Leukemia and Provides Updated Data for Phase 2a Study of SLS009 in Relapsed/Refractory Acute Myeloid Leukemia PatientsJan 10
SELLAS Life Sciences Group, Inc. has completed a Follow-on Equity Offering in the amount of $9 million.Jan 05
SELLAS Life Sciences Group, Inc. Reports Positive Follow-Up Immune Response and Survival Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo® in Advanced Malignant Pleural MesotheliomaDec 28
Sellas Life Sciences Announces First Patients Enrolled in 60 Mg Dose Cohort in Phase 2A Clinical Trial of Sls009 in Acute Myeloid LeukemiaDec 15
Sellas Life Sciences Announces Positive Recommendation from Regal Independent Data Monitoring Committee of Galinpepimut-S in Acute Myeloid LeukemiaDec 05
SELLAS Life Sciences Group, Inc. Reaches Target Enrollment Ex-China in Phase 3 Regal Trial of Galinpepimut-S in Acute Myeloid LeukemiaNov 29
SELLAS Life Sciences Group, Inc. Receives Favorable FDA Type C Meeting Feedback on Chemistry, Manufacturing, and Controls Biologics License Application Filing Strategy for Galinpepimut-SNov 14
SELLAS Life Sciences Group, Inc. Presents Positive Key Immunobiological and Clinical Data from Phase 1/2 Trial of galinpepimut-S in Combination with Keytruda in WT1+ Platinum-Resistant Advanced Ovarian Cancer at International Gynecologic Cancer Society 2023 Annual Global MeetingNov 07
SELLAS Life Sciences Group, Inc. Announces Positive Initial Topline Phase 2a Data of SLS009 in Acute Myeloid LeukemiaOct 17
SELLAS Life Sciences Group, Inc. Provides Update on Phase 3 Regal Clinical Trial for Galinpepimut-S in Acute Myeloid LeukemiaOct 15
SELLAS Announces First Patient Dosed in Phase Ib/II Trial of SLS009 (GFH009) in Relapsed/Refractory Peripheral T-cell LymphomasOct 12
SELLAS Life Sciences Group, Inc. Announces Positive Topline Data in Lymphoma Cohort from Sls009 Phase 1 Dose-Escalation Trial, Supporting Advancement to Phase 2 Clinical Study; Primary and Secondary Endpoints MetSep 22
SELLAS Life Sciences Reports Positive Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo in Advanced Malignant Pleural MesotheliomaJun 29
Sellas Life Sciences Group, Inc. Announces First Patient Dosed in Phase 2A Clinical Trial of GFH009 in Acute Myeloid LeukemiaJun 23
Sellas Life Sciences Group, Inc. Announces Positive Topline Data from Gfh009 Phase 1 Dose-Escalation Trial in Acute Myeloid Leukemia Cohort Supporting Advancement to Phase 2 Clinical StudyMay 05
SELLAS Life Sciences Group, Inc. Appoints Andrew Elnatan as Head of Regulatory Affairs, Chemistry, Manufacturing, and Controls and QualityJan 06
